Rucaparib in relapsed, platinum-sensitive high-grade of international, multicentre, open-label, phase 2 trial

Lancet Oncology, The 18, 75-87 DOI: 10.1016/s1470-2045(16)30559-9

Citation Report

#	Article	IF	CITATIONS
1	PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs, 2017, 77, 113-130.	10.9	44
2	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Research and Treatment, 2017, 162, 597-602.	2.5	38
3	A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 2017, 116, 884-892.	6.4	69
4	Rucaparib: First Global Approval. Drugs, 2017, 77, 585-592.	10.9	61
5	Immunotherapy and epithelial ovarian cancer: a double-edged sword?. Annals of Oncology, 2017, 28, 909-910.	1.2	4
6	PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. Critical Reviews in Oncology/Hematology, 2017, 114, 153-165.	4.4	37
7	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nature Genetics, 2017, 49, 856-865.	21.4	220
8	PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Therapeutic Advances in Medical Oncology, 2017, 9, 253-267.	3.2	78
9	Emerging therapies for breast cancer. Journal of Hematology and Oncology, 2017, 10, 98.	17.0	60
10	The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer. Expert Opinion on Drug Safety, 2017, 16, 687-696.	2.4	9
11	Use of precision methods to accelerate drug development in oncology. Expert Review of Precision Medicine and Drug Development, 2017, 2, 109-120.	0.7	0
12	The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. Current Treatment Options in Oncology, 2017, 18, 27.	3.0	25
13	Ovarian cancer stem cells more questions than answers. Seminars in Cancer Biology, 2017, 44, 67-71.	9.6	128
14	Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. International Journal of Clinical Oncology, 2017, 22, 611-618.	2.2	10
15	Targeting ATR in cancer medicine. Current Problems in Cancer, 2017, 41, 302-315.	2.0	43
16	Oesophageal cancer. Lancet, The, 2017, 390, 2383-2396.	13.7	796
17	PARP Inhibitors in Prostate Cancer. Current Treatment Options in Oncology, 2017, 18, 37.	3.0	50
18	Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2017, 7, 984-998.	9.4	310

ATION RED

#	Article	IF	CITATIONS
19	Unravelling the biology of SCLC: implications for therapy. Nature Reviews Clinical Oncology, 2017, 14, 549-561.	27.6	336
20	Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. Gynecologic Oncology, 2017, 146, 217-224.	1.4	89
21	The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer, 2017, 123, 1912-1924.	4.1	52
22	Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. Clinical Cancer Research, 2017, 23, 1638-1646.	7.0	136
23	Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?. Annals of Oncology, 2017, 28, 920-921.	1.2	1
24	A Phase l–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors. Clinical Cancer Research, 2017, 23, 4095-4106.	7.0	213
25	Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 2017, 116, 1294-1301.	6.4	13
26	Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. European Journal of Cancer, 2017, 76, 52-59.	2.8	10
27	Niraparib for the treatment of ovarian cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 631-640.	1.8	35
28	PARP inhibitors: Synthetic lethality in the clinic. Science, 2017, 355, 1152-1158.	12.6	1,826
28 29	PARP inhibitors: Synthetic lethality in the clinic. Science, 2017, 355, 1152-1158. Targeted Therapies for Ovarian Cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 139-152.	12.6 2.8	1,826 95
28 29 30	PARP inhibitors: Synthetic lethality in the clinic. Science, 2017, 355, 1152-1158. Targeted Therapies for Ovarian Cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 139-152. PARP inhibition â€" moving beyond BRCA-mutated disease. Nature Reviews Clinical Oncology, 2017, 14, 71-71.	12.6 2.8 27.6	1,826 95 2
28 29 30 31	PARP inhibitors: Synthetic lethality in the clinic. Science, 2017, 355, 1152-1158. Targeted Therapies for Ovarian Cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 139-152. PARP inhibition â€" moving beyond BRCA-mutated disease. Nature Reviews Clinical Oncology, 2017, 14, 71-71. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecologic Oncology, 2017, 147, 509-513.	12.6 2.8 27.6 1.4	1,826 95 2 32
28 29 30 31 32	PARP inhibitors: Synthetic lethality in the clinic. Science, 2017, 355, 1152-1158. Targeted Therapies for Ovarian Cancer. Best Practice and Research in Clinical Obstetrics and Cynaecology, 2017, 41, 139-152. PARP inhibition â€" moving beyond BRCA-mutated disease. Nature Reviews Clinical Oncology, 2017, 14, 1-71. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Cynecologic Oncology, 2017, 147, 509-513. Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. Clinical Oncology, 2017, 29, 778-786.	12.6 2.8 27.6 1.4 1.4	1,826 95 2 32 13
28 29 30 31 32 33	PARP inhibitors: Synthetic lethality in the clinic. Science, 2017, 355, 1152-1158. Targeted Therapies for Ovarian Cancer. Best Practice and Research in Clinical Obstetrics and Cynaecology, 2017, 41, 139-152. PARP inhibition â€" moving beyond BRCA-mutated disease. Nature Reviews Clinical Oncology, 2017, 14, 71-71. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Cynecologic Oncology, 2017, 147, 509-513. Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. Clinical Oncology, 2017, 29, 778-786. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Review of Anticancer Therapy, 2017, 17, 1147-1158.	12.6 2.8 27.6 1.4 1.4 2.4	1,826 95 2 32 13 107
28 29 30 31 32 33 33	PARP inhibitors: Synthetic lethality in the clinic. Science, 2017, 355, 1152-1158. Targeted Therapies for Ovarian Cancer. Best Practice and Research in Clinical Obstetrics and Cynaecology, 2017, 41, 139-152. PARP inhibition â€" moving beyond BRCA-mutated disease. Nature Reviews Clinical Oncology, 2017, 14, 1-71. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Cynecologic Oncology, 2017, 147, 509-513. Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. Clinical Oncology, 2017, 29, 778-786. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Review of Anticancer Therapy, 2017, 17, 1147-1158. Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Science, 2017, 108, 2213-2220.	12.6 2.8 27.6 1.4 1.4 2.4 3.9	1,826 95 2 32 13 107 22
28 29 30 31 32 33 33 34	PARP Inhibitors: Synthetic lethality in the clinic. Science, 2017, 355, 1152-1158. Targeted Therapies for Ovarian Cancer. Best Practice and Research in Clinical Obstetrics and Cynaecology, 2017, 41, 139-152. PARP Inhibition â6° moving beyond BRCA-mutated disease. Nature Reviews Clinical Oncology, 2017, 14, 71-71. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Cynecologic Oncology, 2017, 147, 509-513. Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. Clinical Oncology, 2017, 29, 778-786. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Review of Anticancer Therapy, 2017, 17, 1147-1158. Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Science, 2017, 108, 2213-2220. Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients. Drugs and Aging, 2017, 34, 821-831.	12.6 2.8 27.6 1.4 1.4 2.4 3.9 2.7	1,826 95 2 32 32 13 107 22 22

#	Article	IF	CITATIONS
39	The <i>HRD</i> Decision <i>—</i> Which PARP Inhibitor to Use for Whom and When. Clinical Cancer Research, 2017, 23, 7155-7157.	7.0	22
40	Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. European Journal of Cancer, 2017, 86, 5-14.	2.8	49
41	PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecologic Oncology, 2017, 147, 695-704.	1.4	172
42	Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair. Advances in Experimental Medicine and Biology, 2017, 1007, 1-16.	1.6	3
43	FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. Gynecologic Oncology, 2017, 147, 3-10.	1.4	36
44	Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions. Cancer Discovery, 2017, 7, 937-939.	9.4	33
45	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecologic Oncology, 2017, 147, 267-275.	1.4	222
46	Germline genetic variants with implications for disease risk and therapeutic outcomes. Physiological Genomics, 2017, 49, 567-581.	2.3	8
47	PARP inhibitors for targeted treatment in ovarian cancer. Lancet, The, 2017, 390, 1929-1930.	13.7	30
48	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1949-1961.	13.7	1,261
49	Garcinone E induces apoptosis and inhibits migration and invasion in ovarian cancer cells. Scientific Reports, 2017, 7, 10718.	3.3	34
50	Emerging Therapies in the Management of High-Grade Serous Ovarian Carcinoma: a Focus on PARP Inhibitors. Current Obstetrics and Gynecology Reports, 2017, 6, 207-218.	0.8	1
51	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1274-1284.	10.7	1,376
52	FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation–Associated Advanced Ovarian Cancer. Clinical Cancer Research, 2017, 23, 7165-7170.	7.0	133
53	Oesophageal cancer. Nature Reviews Disease Primers, 2017, 3, 17048.	30.5	671
54	Veliparib Monotherapy to Patients With <i>BRCA</i> Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study. International Journal of Gynecological Cancer, 2017, 27, 1842-1849.	2.5	33
55	<i>BRCA</i> mutation in ovarian cancer: testing, implications and treatment considerations. Therapeutic Advances in Medical Oncology, 2017, 9, 519-531.	3.2	96
56	Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clinical Cancer Research, 2017, 23, 6400-6410.	7.0	59

ARTICLE IF CITATIONS # CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and 59 3.3 68 correlation with platinum sensitivity. Scientific Reports, 2017, 7, 16827. Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer. Trends in Molecular Medicine, 2017, 23, 1121-1137. 6.7 48 Optimism and the continued promise of maintenance chemotherapy. Cancer Chemotherapy and 61 2.3 2 Pharmacology, 2017, 80, 879-880. Missing a GOLDen opportunity in gastric cancer. Lancet Oncology, The, 2017, 18, 1561-1563. Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer. 3.0 64 23 Mayo Ćlinic Proceedings, 2017, 92, 1583-1591. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Letters, 2017, 405, 38-45. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of 66 3.6 106 the literature. Gynecologic Oncology Research and Practice, 2017, 4, 4. Germline Testing for Predisposition to Ovarian/Breast Cancer Should be Routinely Recommended in all Patients with Invasive Epithelial Ovarian Cancer. Indian Journal of Gynecologic Oncology, 2017, 15, 0.3 27-30. 68 Treatment of recurrent ovarian cancer. Annals of Oncology, 2017, 28, viii51-viii56. 1.2 200 Whence High-Grade Serous Ovarian Cancer. American Society of Clinical Oncology Educational Book / 3.8 ASCO American Society of Clinical Oncology Meeting, 2017, 37, 443-448. Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical 70 3.8 9 Oncology Meeting, 2017, 37, 358-369. Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. OncoTargets and Therapy, 2017, Volume 10, 3029-3037. 49 Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review. 72 4.1 83 International Journal of Molecular Sciences, 2017, 18, 2171. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers, 2017, 9, 109. 36 Current status of poly(ADP-ribose) polymerase inhibitors and future directions. OncoTargets and 75 2.0 96 Therapy, 2017, Volume 10, 5195-5208. Role and clinical application of next-generation sequencing (NGS) for ovarian cancer. Journal of Gynecologic Oncology, 2017, 28, e51. Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP 77 2.045 inhibition and clinical outcome in ovarian cancer. OncoTargets and Therapy, 2017, Volume 10, 2539-2551. <div>Emerging treatment options for ovarian cancer: focus on rucaparib</div>. International Journal 19 of Women's Health, 2017, Volume 9, 913-924.

#	Article	IF	CITATIONS
79	The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. Oncology Research, 2017, 25, 1441-1451.	1.5	3
80	Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?. Gynecologic Oncology Research and Practice, 2017, 4, 13.	3.6	26
81	PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. Gynecologic Oncology Research and Practice, 2017, 4, 18.	3.6	42
82	Germline Testing for Predisposition to Breast/Ovarian Cancer Should Only be Offered to Selected Patients with Epithelial Ovarian Cancer. Indian Journal of Gynecologic Oncology, 2017, 15, 31-36.	0.3	0
83	Olaparib and somatic BRCA mutations. Oncotarget, 2017, 8, 43598-43599.	1.8	11
84	Drug Monographs: Olaratumab and Rucaparib. Hospital Pharmacy, 2017, 52, 258-263.	1.0	2
85	Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases <i>in vitro</i> toxicity of PARP inhibition by preventing Rad51 foci formation in <i>BRCA</i> wild type high-grade serous ovarian cancer. Oncotarget, 2017, 8, 111026-111040.	1.8	64
86	Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?. Journal of Clinical Oncology, 2017, 35, 3999-4002.	1.6	14
87	Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer. Journal of Clinical Oncology, 2017, 35, 1151-1153.	1.6	2
88	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. Journal of Clinical Oncology, 2017, 35, 2193-2202.	1.6	209
89	The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others. Biomedicine and Pharmacotherapy, 2018, 99, 552-560.	5.6	32
90	The effect of IncRNA HOTAIR on chemoresistance of ovarian cancer through regulation of <i>HOXA7</i> . Biological Chemistry, 2018, 399, 485-497.	2.5	28
92	PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 647-658.	2.3	58
93	Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 18.	0.9	6
94	Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions. Clinical Therapeutics, 2018, 40, 361-371.	2.5	41
95	Rucaparib: a new treatment option for ovarian cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 765-771.	1.8	7
96	A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. Cell Reports, 2018, 23, 918-929.	6.4	39
97	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. Cell Reports, 2018, 23, 100-111.	6.4	60

#	Article	IF	CITATIONS
98	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Reports, 2018, 23, 213-226.e3.	6.4	83
99	Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?. Leukemia, 2018, 32, 1561-1566.	7.2	39
100	Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncology, The, 2018, 19, 207-215.	10.7	167
101	Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecologic Oncology, 2018, 148, 591-600.	1.4	23
103	Rucaparib for the treatment of ovarian cancer. Expert Opinion on Orphan Drugs, 2018, 6, 151-161.	0.8	0
104	Targeting DNA repair: the genome as a potential biomarker. Journal of Pathology, 2018, 244, 586-597.	4.5	41
105	Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). Pathology, 2018, 50, 222-237.	0.6	23
106	Advances in ovarian cancer therapy. Cancer Chemotherapy and Pharmacology, 2018, 81, 17-38.	2.3	393
107	BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. Clinical Breast Cancer, 2018, 18, 184-188.	2.4	34
108	The development of PARP as a successful target for cancer therapy. Expert Review of Anticancer Therapy, 2018, 18, 161-175.	2.4	16
109	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews, 2018, 118, 1599-1663.	47.7	64
110	Proteomic Analysis of the Downstream Signaling Network of PARP1. Biochemistry, 2018, 57, 429-440.	2.5	31
111	Reprogramming T-cells for adoptive immunotherapy of ovarian cancer. Expert Opinion on Biological Therapy, 2018, 18, 359-367.	3.1	5
112	Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. Women's Health, 2018, 14, 174550571775069.	1.5	7
113	Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma. Journal of Molecular Medicine, 2018, 96, 527-536.	3.9	18
114	Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine, 2018, 24, 628-637.	30.7	649
115	Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. Cancer Treatment Reviews, 2018, 66, 7-14.	7.7	51
116	Disparities in genetics assessment for women with ovarian cancer: Can we do better?. Gynecologic Oncology, 2018, 149, 84-88.	1.4	50

#	Article	IF	CITATIONS
117	Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. International Journal of Gynecological Cancer, 2018, 28, 903-914.	2.5	27
118	PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncology Research and Treatment, 2018, 41, 226-234.	1.2	10
121	The Current Landscape of PARP Inhibitors in Ovarian Cancer. Current Obstetrics and Gynecology Reports, 2018, 7, 20-27.	0.8	2
122	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell, 2018, 33, 401-416.e8.	16.8	215
123	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. British Journal of Cancer, 2018, 118, 938-946.	6.4	29
124	Emerging growth factor receptor antagonists for ovarian cancer treatment. Expert Opinion on Emerging Drugs, 2018, 23, 1-16.	2.4	2
125	Neurological complications of new chemotherapy agents. Neuro-Oncology, 2018, 20, 24-36.	1.2	28
126	Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer. Clinical Cancer Research, 2018, 24, 326-333.	7.0	40
127	Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 209-216.	7.0	47
129	Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2018, 20, 274-285.	2.4	5
130	Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2. Advances in Anatomic Pathology, 2018, 25, 85-95.	4.3	24
131	Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. Gynecologic Oncology, 2018, 148, 281-285.	1.4	52
132	PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene, 2018, 37, 341-351.	5.9	98
133	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clinical Cancer Research, 2018, 24, 777-783.	7.0	171
134	Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. Gynecologic Oncology, 2018, 148, 79-85.	1.4	29
135	Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	215
136	Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	129
137	SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine. JCO Precision Oncology, 2018, 2018, 1-14.	3.0	19

#	Article	IF	CITATIONS
138	Sustained Exceptional Response to Poly (ADP-Ribose) Polymerase Inhibition Plus Temozolomide in Metastatic Melanoma With DNA Repair Deficiency. JCO Precision Oncology, 2018, 2, 1-7.	3.0	0
139	Moving From Mutation to Actionability. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 495-503.	3.8	4
140	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. Journal of Gastrointestinal Oncology, 2018, 9, 1198-1206.	1.4	6
141	ATR-FTIR spectroscopy shows changes in ovarian cancer cells after incubation with novel organoamidoplatinum(<scp>ii</scp>) complexes. Analyst, The, 2018, 143, 6087-6094.	3.5	19
142	Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application. , 0, , .		1
143	Significant Tumor Response to the Poly (ADP-ribose) Polymerase Inhibitor Olaparib in Heavily Pretreated Patient With Ovarian Carcinosarcoma Harboring a Germline RAD51D Mutation. JCO Precision Oncology, 2018, 2, 1-4.	3.0	14
144	Reversal of Bowel Obstruction With Platinum-Based Chemotherapy and Olaparib in Recurrent, Short Platinum-Free Interval, RAD51C Germline Mutation–Associated Ovarian Cancer. JCO Precision Oncology, 2018, 2, 1-8.	3.0	5
145	Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer. Gynecologic Oncology Reports, 2018, 26, 91-93.	0.6	8
146	Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Reports, 2018, 25, 2617-2633.	6.4	74
147	Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 1219-1228.	0.9	30
148	Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients. Cancers, 2018, 10, 442.	3.7	30
149	Clinical Utility of Poly (ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer. Journal of Cancer Science & Therapy, 2018, 10, .	1.7	0
150	How safe is rucaparib in ovarian cancer?. Expert Opinion on Drug Safety, 2018, 17, 1249-1255.	2.4	1
151	Targeted treatment of advanced ovarian cancer: spotlight on rucaparib. Therapeutics and Clinical Risk Management, 2018, Volume 14, 2189-2201.	2.0	8
152	Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. PLoS ONE, 2018, 13, e0207399.	2.5	24
153	Management and Treatment of Recurrent Epithelial Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 965-982.	2.2	40
154	Living Through Ovarian Cancer Treatment. Hematology/Oncology Clinics of North America, 2018, 32, 1073-1085.	2.2	4
155	Currently Approved Poly (Adenosine Diphosphate-Ribose) Inhibitors in Ovarian Cancer: Current Status and Future Directions. Clinical Cancer Drugs, 2018, 5, 3-12.	0.3	Ο

ARTICLE IF CITATIONS RAD-ical New Insights into RAD51 Regulation. Genes, 2018, 9, 629. 2.4 98 156 Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. Cancers, 2018, 10, 506. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. 158 3.7 154 Cancers, 2018, 10, 487. Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Research, 2018, 78, 159 0.9 6717-6725. Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors. Current 160 0.2 0 Pharmacogenomics and Personalized Medicine, 2018, 16, 108-117. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Reports, 2018, 25, 2972-2980.e5. 6.4 381 Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Current Treatment Options in 162 3.0 49 Oncology, 2018, 19, 1. Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 1057-1071. Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic 164 0.9 36 Effects in Breast Cancer. Cancer Research, 2018, 78, 6691-6702. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian 12.8 carcinoma. Nature Communications, 2018, 9, 3970. Defective DNA repair in hereditary ovarian cancers: Implications for therapy. American Journal of 166 4 1.0 Health-System Pharmacy, 2018, 75, 1697-1707. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Design, 4.3 26 Development and Therapy, 2018, Volume 12, 3013-3019 Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology and 168 2.3 205 Obstetrics, 2018, 143, 59-78. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. British Journal of Cancer, 2018, 119, 1401-1409. 6.4 Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and 170 1.5 100 management. Clinics, 2018, 73, e450s. Characterisation of homologous recombination deficiency in paired primary and recurrent 171 6.4 high-grade serous ovarian cancer. British Journal of Cancer, 2018, 119, 1060-1066. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. 172 4.1 7 International Journal of Molecular Sciences, 2018, 19, 3249. Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in 2.8 <i>BAP1</i> or other DNA repair genes. Genes Chromosomes and Cancer, 2018, 57, 573-583.

#	Article	IF	CITATIONS
174	Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use. Minerva Obstetrics and Gynecology, 2018, 70, 150-170.	1.0	19
175	A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer and Metastasis Reviews, 2018, 37, 599-614.	5.9	63
176	Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treatment Reviews, 2018, 71, 1-7.	7.7	91
177	Surgical and Medical Management of Epithelial Ovarian Cancer. , 2018, , 884-904.		0
178	Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases. OncoTargets and Therapy, 2018, Volume 11, 1989-1995.	2.0	5
179	Novel Systemic Treatments in High Grade Ovarian Cancer. , 0, , .		0
180	Safety and dose modification for patients receiving niraparib. Annals of Oncology, 2018, 29, 1784-1792.	1.2	125
181	New Therapies for Ovarian Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 632-635.	4.9	8
182	Biomarkers for Homologous Recombination Deficiency in Cancer. Journal of the National Cancer Institute, 2018, 110, 704-713.	6.3	223
183	A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients. Clinical Cancer Research, 2018, 24, 4482-4493.	7.0	91
184	The role of niraparib for the treatment of ovarian cancer. Future Oncology, 2018, 14, 2565-2577.	2.4	10
185	Synthetic lethal therapies for cancer: what's next after PARP inhibitors?. Nature Reviews Clinical Oncology, 2018, 15, 564-576.	27.6	303
186	Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. Journal of Molecular Diagnostics, 2018, 20, 686-702.	2.8	149
187	Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. Journal of Molecular Diagnostics, 2018, 20, 600-611.	2.8	18
188	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. Clinical Oncology, 2018, 30, 515-524.	1.4	16
189	Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls. Journal of Molecular Biology, 2018, 430, 2900-2912.	4.2	21
190	Metastatic gynecologic malignancies: advances in treatment and management. Clinical and Experimental Metastasis, 2018, 35, 521-533.	3.3	11
191	Emerging Molecular Targets for Anti-Cancer Drug Design. Current Chemical Biology, 2018, 12, 88-99.	0.5	0

#	Article	IF	CITATIONS
192	PARP Inhibitors in Epithelial Ovarian Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 145-158.	1.6	35
193	Inherent and toxicant-provoked reduction in DNA repair capacity: A key mechanism for personalized risk assessment, cancer prevention and intervention, and response to therapy. International Journal of Hygiene and Environmental Health, 2018, 221, 993-1006.	4.3	13
194	Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877848.	3.2	23
195	PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. Current Drug Targets, 2018, 19, 21-37.	2.1	100
196	Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878665.	3.2	105
197	Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy. Molecular Cancer Research, 2018, 16, 1103-1111.	3.4	83
198	Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Annals of Oncology, 2018, 29, 1366-1376.	1.2	101
199	Safety and pharmacokinetics of veliparib extendedâ€release in patients with advanced solid tumors: a phase I study. Cancer Medicine, 2018, 7, 2360-2369.	2.8	16
200	Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Design, Development and Therapy, 2018, Volume 12, 1501-1509.	4.3	27
201	Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. Drug Design, Development and Therapy, 2018, Volume 12, 605-617.	4.3	26
202	Copy number signatures and mutational processes in ovarian carcinoma. Nature Genetics, 2018, 50, 1262-1270.	21.4	320
203	Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Clinical Cancer Research, 2018, 24, 6204-6211.	7.0	61
204	Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medicines (Basel, Switzerland), 2018, 5, 16.	1.4	123
205	Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncology, 2018, 14, 3101-3110.	2.4	10
206	BRCAness and prostate cancer: diagnostic and therapeutic considerations. Prostate Cancer and Prostatic Diseases, 2018, 21, 488-498.	3.9	12
207	Emerging therapeutic modalities of PARP inhibitors in breast cancer. Cancer Treatment Reviews, 2018, 68, 62-68.	7.7	28
208	Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?. Cancer Treatment Reviews, 2018, 69, 53-65.	7.7	30
209	Origins based clinical and molecular complexities of epithelial ovarian cancer. International Journal of Biological Macromolecules, 2018, 118, 1326-1345.	7.5	21

#	Article	IF	CITATIONS
210	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine, 2019, 29, 29-39.	4.9	43
211	PARP Inhibition to Enhance Response to Chemotherapy. , 2019, , 231-257.		1
212	Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors. Clinical Pharmacology in Drug Development, 2019, 8, 107-118.	1.6	30
213	Implementing precision cancer medicine in the genomic era. Seminars in Cancer Biology, 2019, 55, 16-27.	9.6	24
214	Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers. Expert Opinion on Therapeutic Targets, 2019, 23, 773-785.	3.4	22
215	Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting. Gynecologic Oncology Reports, 2019, 29, 123-125.	0.6	3
216	Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer. Journal of Clinical Oncology, 2019, 37, 2424-2436.	1.6	29
217	The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers. Journal of Clinical Oncology, 2019, 37, 2449-2459.	1.6	13
218	Update on Genetic Testing in Gynecologic Cancer. Journal of Clinical Oncology, 2019, 37, 2501-2509.	1.6	26
219	Diverse mechanisms of PARP inhibitor resistance in ovarian cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1872, 188307.	7.4	14
220	Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors. Current Oncology Reports, 2019, 21, 83.	4.0	22
221	Site-specific analysis of the Asp- and Glu-ADP-ribosylated proteome by quantitative mass spectrometry. Methods in Enzymology, 2019, 626, 301-321.	1.0	9
222	Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. Translational Oncology, 2019, 12, 1386-1394.	3.7	7
223	<p>Evidence to date: talazoparib in the treatment of breast cancer</p> . OncoTargets and Therapy, 2019, Volume 12, 5177-5187.	2.0	30
224	Overcoming Resistance to PARP Inhibition. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 161-189.	0.1	0
226	Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. International Journal of Gynecological Cancer, 2019, 29, 956-968.	2.5	4
227	PARP-1 and its associated nucleases in DNA damage response. DNA Repair, 2019, 81, 102651.	2.8	122
228	Fallopian Tube Carcinoma. Journal of Oncology Practice, 2019, 15, 375-382.	2.5	28

#	Article	IF	CITATIONS
229	The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report. Journal of Gynecologic Oncology, 2019, 30, e91.	2.2	5
230	Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. International Journal of Molecular Sciences, 2019, 20, 3100.	4.1	32
232	PARP Inhibition in Cancer: An Update on Clinical Development. Targeted Oncology, 2019, 14, 657-679.	3.6	133
233	ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer. Nature Communications, 2019, 10, 4632.	12.8	21
235	Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives $\hat{a} \in $ a review. Journal of Ovarian Research, 2019, 12, 103.	3.0	68
236	Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility. Gynecologic Oncology, 2019, 155, 473-482.	1.4	3
237	Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints. Expert Opinion on Investigational Drugs, 2019, 28, 771-785.	4.1	9
238	Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies. Frontiers in Pharmacology, 2019, 10, 426.	3.5	21
239	PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecologic Oncology, 2019, 155, 144-150.	1.4	28
240	Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization. Lung Cancer, 2019, 137, 48-51.	2.0	22
241	Prospects for combining immune checkpoint blockade with PARP inhibition. Journal of Hematology and Oncology, 2019, 12, 98.	17.0	92
242	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2403-2415.	27.0	627
243	Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer, 2019, 19, 901.	2.6	33
244	Prevalence of germline pathogenic <i>BRCA1/2</i> variants in sequential epithelial ovarian cancer cases. Journal of Medical Genetics, 2019, 56, 301-307.	3.2	21
245	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecologic Oncology, 2019, 153, 127-134.	1.4	56
246	Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. Journal of Ovarian Research, 2019, 12, 9.	3.0	83
247	Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas. International Journal of Cancer, 2019, 145, 1209-1220.	5.1	23
248	PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. Journal of Cellular and Molecular Medicine, 2019, 23, 2303-2313.	3.6	103

#	Article	IF	CITATIONS
249	Ovarian Cancer. Obstetrics and Gynecology Clinics of North America, 2019, 46, 67-88.	1.9	12
250	Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care. Obstetrics and Gynecology Clinics of North America, 2019, 46, 137-154.	1.9	3
251	Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications. Current Opinion in Obstetrics and Gynecology, 2019, 31, 12-17.	2.0	7
253	A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology, 2019, 30, 1437-1447.	1.2	437
254	Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. ESMO Open, 2019, 4, e000480.	4.5	47
255	Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United Statesâ€. Pharmacoeconomics, 2019, 37, 1065-1067.	3.3	6
256	Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers. Methods in Molecular Biology, 2019, 1999, 3-29.	0.9	3
257	Ovarian cancer relapse: From the latest scientific evidence to the best practice. Critical Reviews in Oncology/Hematology, 2019, 140, 28-38.	4.4	31
258	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2019, 140, 39-51.	4.4	11
259	Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations. BMC Cancer, 2019, 19, 535.	2.6	77
260	PARP Inhibitors in Ovarian Cancer: The Route to "lthaca― Diagnostics, 2019, 9, 55.	2.6	52
261	Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes. BMC Cancer, 2019, 19, 422.	2.6	22
262	Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. Genetics and Molecular Biology, 2019, 42, 215-231.	1.3	14
263	Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies. Targeted Oncology, 2019, 14, 269-283.	3.6	8
264	The DNA Damaging Revolution: PARP Inhibitors and Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 185-195.	3.8	144
265	Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e152-e166.	3.8	12
266	Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	20
267	The Drug-Diagnostic Codevelopment Model. , 2019, , 11-25.		0

#	Article	IF	CITATIONS
268	Companion Diagnostics Assay Development—Prototype, Verification, and Analytical Validation. , 2019, , 243-263.		0
269	Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Management and Research, 2019, Volume 11, 4371-4390.	1.9	77
270	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precision Oncology, 2019, 3, 1-23.	3.0	63
271	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2019, 69, 280-304.	329.8	821
272	Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. Scientific Reports, 2019, 9, 6314.	3.3	33
273	ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology, 2019, 30, 672-705.	1.2	665
274	ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. International Journal of Gynecological Cancer, 2019, 29, 728-760.	2.5	167
275	Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients. International Journal of Gynecological Cancer, 2019, 29, 325-333.	2.5	13
276	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. Biochemical Pharmacology, 2019, 167, 133-148.	4.4	19
277	Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Annals of Oncology, 2019, 30, 721-732.	1.2	53
278	Ovarian Cancer Maintenance: Practice hanging Data Calls for Changing Practice. Oncologist, 2019, 24, 576-579.	3.7	0
279	Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. International Journal of Biological Sciences, 2019, 15, 962-972.	6.4	10
280	Cancer Treatment in the Genomic Era. Annual Review of Biochemistry, 2019, 88, 247-280.	11.1	24
281	PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review. BioDrugs, 2019, 33, 255-273.	4.6	31
282	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer, 2019, 125, 1963-1972.	4.1	39
283	RAD51D splice variants and cancer-associated mutations reveal XRCC2 interaction to be critical for homologous recombination. DNA Repair, 2019, 76, 99-107.	2.8	13
284	Rucaparib: A Review in Ovarian Cancer. Targeted Oncology, 2019, 14, 237-246.	3.6	26
285	Analysis of BRCAness with multiplex ligation-dependent probe amplification using formalin-fixed and paraffin-embedded pancreatic ductal adenocarcinoma tissue obtained via endoscopic ultrasound-guided fine-needle aspiration biopsy. Pancreatology. 2019. 19. 419-423.	1.1	3

			-
#	ARTICLE	IF	CITATIONS
286	Epithelial ovarian cancer. Lancet, The, 2019, 393, 1240-1253.	13.7	1,039
287	Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers, 2019, 11, 416.	3.7	49
288	Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Current Oncology Reports, 2019, 21, 42.	4.0	15
289	Genetic predisposition for malignant mesothelioma: A concise review. Mutation Research - Reviews in Mutation Research, 2019, 781, 1-10.	5.5	30
290	Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncology, The, 2019, 20, 570-580.	10.7	191
291	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. Annals of Hematology, 2019, 98, 1383-1392.	1.8	9
292	New and Novel Therapies for Gynecologic Cancers. Seminars in Oncology Nursing, 2019, 35, 217-219.	1.5	10
293	Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types. Cancers, 2019, 11, 354.	3.7	12
294	Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies. , 2019, 200, 27-41.		53
295	Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open, 2019, 4, e000444.	4.5	8
296	Rucaparib in the landscape of PARP inhibition in ovarian cancer. Expert Review of Anticancer Therapy, 2019, 19, 437-446.	2.4	2
297	Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. Clinical Cancer Research, 2019, 25, 5441-5448.	7.0	217
298	The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. International Journal of Gynecological Cancer, 2019, 29, 166-173.	2.5	17
299	PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. Journal of Clinical Medicine, 2019, 8, 435.	2.4	106
300	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. Endocrine Connections, 2019, 8, R10-R26.	1.9	33
301	ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. Gynecologic Oncology, 2019, 153, 416-424.	1.4	26
302	Integrated structural variation and point mutation signatures in cancer genomes using correlated topic models. PLoS Computational Biology, 2019, 15, e1006799.	3.2	44
303	An Advanced Strategy for Comprehensive Profiling of ADP-ribosylation Sites Using Mass Spectrometry-based Proteomics*. Molecular and Cellular Proteomics, 2019, 18, 1010a-1026.	3.8	113

#	Article	IF	CITATIONS
304	Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. Gynecologic Oncology, 2019, 153, 217-222.	1.4	38
305	The role of dePARylation in DNA damage repair and cancer suppression. DNA Repair, 2019, 76, 20-29.	2.8	7
306	Major clinical research advances in gynecologic cancer in 2018. Journal of Gynecologic Oncology, 2019, 30, e18.	2.2	29
307	Homologous recombination deficiency in triple negative breast cancer. Breast, 2019, 45, 15-21.	2.2	58
308	Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors. Expert Review of Precision Medicine and Drug Development, 2019, 4, 11-25.	0.7	1
309	Treatment of recurrent epithelial ovarian cancer. Cancer, 2019, 125, 4609-4615.	4.1	49
310	Pan-Cancer Analysis of <i>CDK12</i> Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. Oncologist, 2019, 24, 1526-1533.	3.7	39
311	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i> -mutated, high-grade ovarian cancer, and an update on safety. International Journal of Gynecological Cancer, 2019, 29, 1396-1404.	2.5	19
312	Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review. Asian Journal of Oncology, 2019, 05, 01-18.	0.2	0
313	Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. BMJ Case Reports, 2019, 12, e230738.	0.5	18
314	Advances and perspectives of PARP inhibitors. Experimental Hematology and Oncology, 2019, 8, 29.	5.0	81
315	Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors. Frontiers in Oncology, 2019, 9, 1097.	2.8	13
316	Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. Cancers, 2019, 11, 1980.	3.7	29
317	Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer. Anti-Cancer Drugs, 2019, 30, 554-561.	1.4	2
318	Clinical Applications of Next-Generation Sequencing in Precision Oncology. Cancer Journal (Sudbury,) Tj ETQq0 0	0 rgBT /O	verlock 10 Tf
319	Current role of poly(ADP-ribose) polymerase inhibitors. Current Opinion in Oncology, 2019, 31, 394-403.	2.4	2
320	Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study. JCO Precision Oncology, 2019, 3, 1-18.	3.0	0
321	Challenges in the identification of inherited risk of ovarian cancer: where should we go from here?. Gynecologic Oncology, 2019, 152, 3-6.	1.4	1

#	Article	IF	CITATIONS
322	Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing. Journal of Molecular Diagnostics, 2019, 21, 198-213.	2.8	2
323	Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. Journal of Medical Economics, 2019, 22, 187-195.	2.1	7
324	Exploring and comparing adverse events between PARP inhibitors. Lancet Oncology, The, 2019, 20, e15-e28.	10.7	287
325	EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Research, 2019, 79, 819-829.	0.9	52
326	Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review. Gynecologic Oncology, 2019, 152, 416-425.	1.4	31
327	Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. Clinical Cancer Research, 2019, 25, 1087-1097.	7.0	113
328	Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer. , 2019, , 521-532.		2
329	New Treatment Options for Ovarian Cancer. , 2019, , 533-540.		0
330	Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 371-378.	2.4	37
331	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2019, 9, 210-219.	9.4	278
332	Evaluation of Drug–Drug Interactions of Rucaparib and <scp>CYP</scp> 1A2, <scp>CYP</scp> 2C9, <scp>CYP</scp> 2C19, <scp>CYP</scp> 3A, and Pâ€gp Substrates in Patients With an Advanced Solid Tumor. Clinical and Translational Science, 2019, 12, 58-65.	3.1	17
333	Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Critical Reviews in Oncology/Hematology, 2019, 133, 171-182.	4.4	93
334	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. European Journal of Clinical Pharmacology, 2019, 75, 697-706.	1.9	3
335	Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors. Biochemical Pharmacology, 2019, 167, 125-132.	4.4	9
336	State-of-the-art strategies for targeting the DNA damage response in cancer. Nature Reviews Clinical Oncology, 2019, 16, 81-104.	27.6	736
338	PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. Journal of Geriatric Oncology, 2019, 10, 337-345.	1.0	25
339	The Fanconi Anemia Pathway in Cancer. Annual Review of Cancer Biology, 2019, 3, 457-478.	4.5	261
340	Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. Gynecologic Oncology, 2019, 152, 270-277.	1.4	12

#	Article	IF	CITATIONS
341	PARP inhibitors in ovarian cancer. Cancer Treatment Reviews, 2019, 73, 1-9.	7.7	158
342	Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer. Journal of Pharmacy Practice, 2019, 32, 219-224.	1.0	4
343	Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. Oncologist, 2020, 25, e109-e119.	3.7	13
344	Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gynecologic Oncology, 2020, 156, 488-497.	1.4	51
345	PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. Cancer Letters, 2020, 469, 124-133.	7.2	22
346	Genetic Factors. , 2020, , 180-208.e11.		4
347	Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR. Journal of Pathology: Clinical Research, 2020, 6, 3-11.	3.0	5
348	PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. Journal of Oncology Pharmacy Practice, 2020, 26, 718-729.	0.9	13
349	Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making. Gynecologic Oncology, 2020, 156, 517-522.	1.4	16
350	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. Translational Oncology, 2020, 13, 410-422.	3.7	52
351	Latest clinical evidence of maintenance therapy in ovarian cancer. Current Opinion in Obstetrics and Gynecology, 2020, 32, 15-21.	2.0	19
352	Prediction of Epithelial Ovarian Cancer Outcomes With Integration of Genomic Data. Clinical Obstetrics and Gynecology, 2020, 63, 92-108.	1.1	6
353	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research, 2020, 26, 1372-1384.	7.0	66
354	Biomarkers that may predict response to immunotherapy in ovarian malignancies. Current Opinion in Obstetrics and Gynecology, 2020, 32, 84-90.	2.0	8
355	Comprehensive profiling of <i>BRCA1 and BRCA2</i> variants in breast and ovarian cancer in Chinese patients. Human Mutation, 2020, 41, 696-708.	2.5	21
356	Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 195-202	2.8	12
357	An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer. Gynecologic Oncology, 2020, 156, 222-232.	1.4	37
358	P5 eHealth: An Agenda for the Health Technologies of the Future. , 2020, , .		21

#	Article	IF	CITATIONS
359	Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. Gynecologic Oncology, 2020, 156, 415-422.	1.4	28
360	Recent advancements in PARP inhibitors-based targeted cancer therapy. Precision Clinical Medicine, 2020, 3, 187-201.	3.3	26
361	Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecologic Oncology, 2020, 159, 887-898.	1.4	70
362	Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network. Journal of Clinical Pathology, 2020, 74, jclinpath-2020-206800.	2.0	3
363	New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 578095.	2.8	36
364	Newly diagnosed ovarian cancer: Which first-line treatment?. Cancer Treatment Reviews, 2020, 91, 102111.	7.7	23
365	Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy. International Journal of Pharmaceutics, 2020, 591, 119986.	5.2	30
366	Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. Life Sciences, 2020, 261, 118434.	4.3	23
367	The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. Cancer Biology and Medicine, 2020, 17, 1002-1013.	3.0	18
368	<p>Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety</p> . OncoTargets and Therapy, 2020, Volume 13, 9857-9863.	2.0	10
369	ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology, 2020, 31, 1606-1622.	1.2	238
370	The DNA damaging revolution. Critical Reviews in Oncology/Hematology, 2020, 156, 103117.	4.4	9
371	Homologous recombination deficiency real-time clinical assays, ready or not?. Gynecologic Oncology, 2020, 159, 877-886.	1.4	39
372	Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA. Oncogene, 2020, 39, 7051-7062.	5.9	18
373	Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review. Journal of Oncology Pharmacy Practice, 2020, 26, 1977-1986.	0.9	5
374	Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system. Gynecologic Oncology, 2020, 158, 747-753.	1.4	12
375	Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. European Journal of Human Genetics, 2020, 28, 1541-1547.	2.8	22
376	Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma. International Journal of Molecular Sciences, 2020, 21, 4910.	4.1	45

		15	C
Ŧ	ARTICLE	IF	CHATIONS
377	cancer treated with PARP-inhibitors and immunotherapy. Heliyon, 2020, 6, e03841.	3.2	10
379	DNA damaging agents in ovarian cancer. European Journal of Cancer, Supplement, 2020, 15, 67-72.	2.2	2
380	Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers. Seminars in Cancer Biology, 2020, 77, 110-126.	9.6	16
381	Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens. Nature Communications, 2020, 11, 6118.	12.8	39
382	Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts. Journal of Clinical Medicine, 2020, 9, 2377.	2.4	1
383	Discovery through clinical sequencing in oncology. Nature Cancer, 2020, 1, 774-783.	13.2	29
384	Rucaparib antagonize multidrug resistance in cervical cancer cells through blocking the function of ABC transporters. Gene, 2020, 759, 145000.	2.2	9
385	Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. JCO Precision Oncology, 2020, 4, 882-897.	3.0	22
386	Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduction and Targeted Therapy, 2020, 5, 137.	17.1	79
387	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecologic Oncology, 2020, 159, 79-87.	1.4	6
388	BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer. Breast Cancer Research, 2020, 22, 79.	5.0	8
389	Financial Toxicity Encountered in Therapeutic Radiopharmaceutical Clinical Development for Ovarian Cancer. Pharmaceuticals, 2020, 13, 181.	3.8	2
390	PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 3468-3493.	1.6	175
391	XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells. NAR Cancer, 2020, 2, zcaa013.	3.1	36
392	Synthetic Lethality through the Lens of Medicinal Chemistry. Journal of Medicinal Chemistry, 2020, 63, 14151-14183.	6.4	31
393	Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer. Cancers, 2020, 12, 3046.	3.7	22
394	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology, 2020, 38, 4274-4282.	1.6	276
396	Anti-angiogenic therapy for ovarian cancer. European Journal of Cancer, Supplement, 2020, 15, 77-86.	2.2	8

#	Article	IF	CITATIONS
397	Poly(ADP-ribose) polymerase inhibition: past, present and future. Nature Reviews Drug Discovery, 2020, 19, 711-736.	46.4	275
398	Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. Journal of Hematology and Oncology, 2020, 13, 118.	17.0	95
399	Secondary and tertiary ovarian cancer recurrence: what is the best management?. Gland Surgery, 2020, 9, 1118-1129.	1.1	18
400	Development of new medical treatment for epithelial ovarian cancer recurrence. Gland Surgery, 2020, 9, 1149-1163.	1.1	12
401	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. Journal of the National Cancer Institute, 2020, 112, 1190-1203.	6.3	32
402	The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. International Journal of Gynecological Cancer, 2020, 30, 1608-1618.	2.5	4
403	PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies. Chinese Clinical Oncology, 2020, 9, 51-51.	1.2	4
404	A new targeted treatment for patients with a germline <i>BRCA</i> mutation: olaparib in pancreatic cancer. Future Oncology, 2020, 16, 2691-2700.	2.4	1
405	Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?. Current Opinion in Oncology, 2020, 32, 442-450.	2.4	10
406	Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives. Cancers, 2020, 12, 2414.	3.7	10
407	Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?. Archives of Gynecology and Obstetrics, 2020, 302, 1087-1102.	1.7	31
408	BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine, 2020, 60, 102988.	6.1	27
409	Breast cancer (BRCA) gene testing in ovarian cancer. Chinese Clinical Oncology, 2020, 9, 63-63.	1.2	3
410	<p>Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma</p> . International Journal of Nanomedicine, 2020, Volume 15, 5561-5571.	6.7	8
411	Molecular Features and Clinical Management of Hereditary Gynecological Cancers. International Journal of Molecular Sciences, 2020, 21, 9504.	4.1	13
412	BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. International Journal of Molecular Sciences, 2020, 21, 9708.	4.1	17
413	Treatment of Recurrent Epithelial Ovarian Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1195-1204.	1.8	13
414	Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets. Seminars in Cancer Biology, 2021, 77, 29-41.	9.6	27

"		15	Cizizione
#		IF	CITATIONS
415	Targeted Molecular Therapy in Palliative Cancer Management. , 2020, 5, .		1
416	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 4135-4142.	7.0	95
417	BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. Journal of Ovarian Research, 2020, 13, 50.	3.0	64
418	PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e116-e131.	3.8	30
419	Therapeutic applications of PARP inhibitors in ovarian cancer. Biomedicine and Pharmacotherapy, 2020, 127, 110204.	5.6	29
420	<p>BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects</p> . Cancer Management and Research, 2020, Volume 12, 2731-2742.	1.9	69
421	Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. JCO Precision Oncology, 2020, 4, 442-465.	3.0	103
422	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. Clinical Cancer Research, 2020, 26, 4268-4279.	7.0	126
423	Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. Breast Cancer Research and Treatment, 2020, 182, 491-502.	2.5	2
424	Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers, 2020, 12, 1206.	3.7	6
425	Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecologic Oncology, 2020, 158, 16-24.	1.4	40
426	Biomarker-Guided Development of DNA Repair Inhibitors. Molecular Cell, 2020, 78, 1070-1085.	9.7	157
427	Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nature Communications, 2020, 11, 2662.	12.8	157
428	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nature Communications, 2020, 11, 2641.	12.8	90
429	Genomics-guided pre-clinical development of cancer therapies. Nature Cancer, 2020, 1, 482-492.	13.2	23
430	PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?. Cancers, 2020, 12, 1378.	3.7	29
431	HRness in Breast and Ovarian Cancers. International Journal of Molecular Sciences, 2020, 21, 3850.	4.1	14
432	Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors. Expert Opinion on Emerging Drugs, 2020, 25, 165-188.	2.4	10

#	Article	IF	CITATIONS
433	Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance. Targeted Oncology, 2020, 15, 391-406.	3.6	11
434	Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092198.	3.2	8
435	The forefront of ovarian cancer therapy: update on PARP inhibitors. Annals of Oncology, 2020, 31, 1148-1159.	1.2	191
436	The emerging role of precision medicine in the treatment of ovarian cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 283-297.	0.7	3
437	Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells, 2020, 9, 1402.	4.1	46
438	Wnt Signaling in Gynecologic Malignancies. International Journal of Molecular Sciences, 2020, 21, 4272.	4.1	45
439	BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy. JNCI Cancer Spectrum, 2020, 4, pkz100.	2.9	7
440	Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. International Journal of Biological Sciences, 2020, 16, 1363-1375.	6.4	22
441	Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. International Journal of Gynecological Cancer, 2020, 30, 684-694.	2.5	6
442	Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells, 2020, 9, 719.	4.1	43
443	Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer. Cancers, 2020, 12, 707.	3.7	14
444	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. Drugs in R and D, 2020, 20, 55-73.	2.2	84
445	Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer. Theranostics, 2020, 10, 3939-3951.	10.0	35
446	Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. BMC Cancer, 2020, 20, 204.	2.6	25
447	The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity. Cancers, 2020, 12, 564.	3.7	12
448	Evaluation of <i>inÂvitro</i> absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor. Xenobiotica, 2020, 50, 1032-1042.	1.1	25
449	Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer. Frontiers in Oncology, 2020, 10, 958.	2.8	9
450	Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer. Frontiers in Oncology, 2020, 10, 954.	2.8	8

#	Article	IF	CITATIONS
451	The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2020, 18, 151.	1.9	14
452	A GLOBAL DIGEST ON APPROACHES IN ADVANCED SOLID TUMORS. Report from the ESMO 2019 Congress, Barcelona, September 27th – October 1st 2019. Memo - Magazine of European Medical Oncology, 2020, 13, 1-22.	0.5	0
453	PARP and PARG inhibitors in cancer treatment. Genes and Development, 2020, 34, 360-394.	5.9	360
454	Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing. BioMed Research International, 2020, 2020, 1-10.	1.9	7
455	PARP inhibitors: a tsunami of indications in different malignancies. Pharmacogenomics, 2020, 21, 221-230.	1.3	16
456	A profile on the FoundationFocus CDxBRCA tests. Expert Review of Molecular Diagnostics, 2020, 20, 285-292.	3.1	15
457	PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?. Current Oncology Reports, 2020, 22, 29.	4.0	14
458	The kinase polypharmacology landscape of clinical PARP inhibitors. Scientific Reports, 2020, 10, 2585.	3.3	68
459	Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. Journal of Clinical Oncology, 2020, 38, 1164-1174.	1.6	194
460	The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication. Nature Reviews Molecular Cell Biology, 2020, 21, 284-299.	37.0	199
461	CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes. Gynecologic Oncology, 2020, 157, 405-410.	1.4	30
462	A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. Gynecologic Oncology, 2020, 157, 214-221.	1.4	2
463	Enabling Precision Oncology Through Precision Diagnostics. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 97-121.	22.4	50
464	Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1222-1245.	1.6	202
465	Association between DNA damage repair gene somatic mutations and immuneâ€related gene expression in ovarian cancer. Cancer Medicine, 2020, 9, 2190-2200.	2.8	27
466	Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 147, 102888.	4.4	13
467	Higher prevalence of homologous recombination deficiency in tumors from African Americans versus European Americans. Nature Cancer, 2020, 1, 112-121.	13.2	30
468	Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?. Current Treatment Options in Oncology, 2020, 21, 49.	3.0	7

#	Article	IF	CITATIONS
469	The tubal epigenome $\hat{a} \in $ An emerging target for ovarian cancer. , 2020, 210, 107524.		10
470	Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. Gynecologic Oncology, 2020, 157, 500-507.	1.4	23
471	Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). International Journal of Gynecological Cancer, 2020, 30, 509-514.	2.5	9
472	Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. International Journal of Gynecological Cancer, 2020, 30, 903-915.	2.5	52
473	Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers, 2020, 12, 972.	3.7	14
474	BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. Breast Cancer Research and Treatment, 2020, 181, 323-329.	2.5	9
475	Recommendations to improve the clinical adoption of NGSâ€based cancer diagnostics in Singapore. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 222-231.	1.1	8
476	The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Annals of Surgical Oncology, 2020, 27, 1780-1787.	1.5	13
477	Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. Frontiers in Cell and Developmental Biology, 2020, 8, 160.	3.7	46
478	The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. Cancer, 2020, 126, 2553-2560.	4.1	11
479	The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer. Pharmacoeconomics, 2021, 39, 231-241.	3.3	3
480	Parthanatos and its associated components: Promising therapeutic targets for cancer. Pharmacological Research, 2021, 163, 105299.	7.1	50
481	PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a metaâ€analysis. BJOC: an International Journal of Obstetrics and Gynaecology, 2021, 128, 485-493.	2.3	23
482	Tumor and germline next generation sequencing in high grade serous cancer: experience from a large populationâ€based testing program. Molecular Oncology, 2021, 15, 80-90.	4.6	14
483	Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. Modern Pathology, 2021, 34, 983-993.	5.5	11
484	The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. Gynecologic Oncology, 2021, 160, 333-345.	1.4	40
485	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. Oncologist, 2021, 26, e394-e402.	3.7	39
486	Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology, 2021, 157, 103145.	4.4	34

#	Article	IF	CITATIONS
487	Current Ovarian Cancer Maintenance Strategies and Promising New Developments. Journal of Cancer, 2021, 12, 38-53.	2.5	36
489	PARP inhibitors and the Kidney. Journal of Onco-Nephrology, 2021, 5, 42-47.	0.6	4
490	Comments on: Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer. Journal of Gynecologic Oncology, 2021, 32, e33.	2.2	0
491	DNA Damage Repair Inhibitor for Breast Cancer Treatment. Advances in Experimental Medicine and Biology, 2021, 1187, 159-179.	1.6	0
492	Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in <i>TP53-</i> and <i>BRCA1</i> -Deficient Cells. Cancer Research, 2021, 81, 2774-2787.	0.9	17
493	Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Experimental and Molecular Medicine, 2021, 53, 42-51.	7.7	93
494	How to sequence treatment in relapsed ovarian cancer. Future Oncology, 2021, 17, 1-8.	2.4	1
495	Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview. Advances in Experimental Medicine and Biology, 2021, 1330, 1-19.	1.6	1
496	Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids. , 2021, , .		0
497	Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes—Practice resource of the National Society of Genetic Counselors. Journal of Genetic Counseling, 2021, 30, 342-360.	1.6	18
498	The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer. Breast Cancer Research and Treatment, 2021, 185, 869-877.	2.5	2
499	Next-generation sequencing: an expedition from workstation to clinical applications. , 2021, , 29-47.		5
500	Text Analytics and Mixed Feature Extraction in Ovarian Cancer Clinical and Genetic Data. IEEE Access, 2021, 9, 58034-58051.	4.2	2
501	<scp>PARP</scp> inhibitors in ovarian cancer: An overview of the practiceâ€changing trials. Genes Chromosomes and Cancer, 2021, 60, 385-397.	2.8	51
502	Homologous recombination repair deficiency (HRD): From biology to clinical exploitation. Genes Chromosomes and Cancer, 2021, 60, 299-302.	2.8	16
503	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. Seminars in Cancer Biology, 2021, 77, 67-82.	9.6	12
504	Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer. Journal of Personalized Medicine, 2021, 11, 149.	2.5	16
505	Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors. PLoS ONE, 2021, 16, e0246048.	2.5	0

#	Article	IF	CITATIONS
506	Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation. Cancers, 2021, 13, 1004.	3.7	28
508	Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. Scientific Reports, 2021, 11, 4219.	3.3	37
509	Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. Cancers, 2021, 13, 1420.	3.7	7
510	Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. Cancers, 2021, 13, 1298.	3.7	24
511	Long-Term Follow-Up of a Female Patient Treated with Olaparib—Hope for a Long Life without Relapse?. International Journal of Environmental Research and Public Health, 2021, 18, 3430.	2.6	1
512	Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2021, 27, 3201-3214.	7.0	27
513	Molecular disruption of DNA polymerase Î ² for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. Oncogene, 2021, 40, 2496-2508.	5.9	12
515	Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know. Expert Opinion on Investigational Drugs, 2021, 30, 543-554.	4.1	13
516	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 3234-3242.	7.0	24
517	Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. Drug Resistance Updates, 2021, 55, 100744.	14.4	43
518	Avoid the trap: Targeting PARP1 beyond human malignancy. Cell Chemical Biology, 2021, 28, 456-462.	5.2	12
519	Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review. Cancers, 2021, 13, 2067.	3.7	7
521	Identification of ubiquitination-related genes in human glioma as indicators of patient prognosis. PLoS ONE, 2021, 16, e0250239.	2.5	7
522	FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. Cancers, 2021, 13, 1866.	3.7	12
523	Genetic alterations and their therapeutic implications in epithelial ovarian cancer. BMC Cancer, 2021, 21, 499.	2.6	27
524	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature Communications, 2021, 12, 2487.	12.8	116
527	Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. Journal of Clinical Oncology, 2021, 39, 1631-1640.	1.6	62
528	Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC Cancer, 2021, 21, 593.	2.6	34

		CITATION R	EPORT	
#	ARTICLE		IF	Citations
529	Present and Future for PARP Inhibitors in Ovarian Cancer. Advances in Oncology, 2021	., 1, 139-154.	0.2	0
530	DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancr Adenocarcinoma. Pancreas, 2021, 50, e50-e52.	eatic Ductal	1.1	1
531	Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as mainter women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. A Gynecology and Obstetrics, 2021, 304, 285-296.	hance therapy in Archives of	1.7	10
532	Estrogen enhances the cytotoxicity of PARP inhibitors on breast cancer cells through s nitric oxide production. Journal of Steroid Biochemistry and Molecular Biology, 2021, 2	timulating 209, 105853.	2.5	8
533	PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinica Oncology, 2021, 117, 105292.	l data. Oral	1.5	21
534	The role of homologous recombination deficiency testing in ovarian cancer and its clin implications: do we need it?. ESMO Open, 2021, 6, 100144.	ical	4.5	77
535	The systemic treatment of recurrent ovarian cancer revisited. Annals of Oncology, 202	1, 32, 710-725.	1.2	61
536	Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial multi-institution health-system. Journal of Oncology Pharmacy Practice, 2022, 28, 110	cancer within a 2-1110.	0.9	1
537	Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endor Current Drug Targets, 2022, 23, 145-155.	netrial Cancer.	2.1	5
538	Structural Chromosome Instability: Types, Origins, Consequences, and Therapeutic Op Cancers, 2021, 13, 3056.	portunities.	3.7	26
539	Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma. JCC Oncology, 2021, 5, 1013-1023.) Precision	3.0	3
540	Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patien platinum-resistant ovarian cancer: primaryÂanalysis of FORWARD I. Annals of Oncolog 757-765.	nts with y, 2021, 32,	1.2	105
541	Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor t ovarian cancer. American Journal of Obstetrics and Gynecology, 2021, 225, 68.e1-68.e	reatment in 11.	1.3	10
542	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nature Clinical Oncology, 2021, 18, 773-791.	e Reviews	27.6	198
543	Androgen/Androgen Receptor Signaling in Ovarian Cancer: Molecular Regulation and T Potentials. International Journal of Molecular Sciences, 2021, 22, 7748.	herapeutic	4.1	23
544	Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model development of PARP inhibitor resistance. NAR Cancer, 2021, 3, zcab028.	during	3.1	20
545	PGK1 Is a Key Target for Anti-Glycolytic Therapy of Ovarian Cancer: Based on the Comp Analysis of Glycolysis-Related Genes. Frontiers in Oncology, 2021, 11, 682461.	prehensive	2.8	17
546	The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patie Cancer?. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 87	nts With /1-878.	4.9	10

#	Article	IF	CITATIONS
547	Tumor Treating Fields for Ovarian Carcinoma: A Modeling Study. Advances in Radiation Oncology, 2021, 6, 100716.	1.2	4
548	Emerging role of PARPâ€1 and PARthanatos in ischemic stroke. Journal of Neurochemistry, 2022, 160, 74-87.	3.9	39
549	Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells. Cancer Research and Treatment, 2021, 53, 819-828.	3.0	5
550	Predictive Value of HE4 in Platinum-Based Chemotherapy for Ovarian Cancer: A Systematic Review. Frontiers in Oncology, 2021, 11, 703949.	2.8	2
551	MicroRNA‑139‑5p improves sepsis‑induced lung injury by targeting Rho‑kinase1. Experimental and Therapeutic Medicine, 2021, 22, 1059.	1.8	7
552	Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. Cancer Research, 2021, 81, 4709-4722.	0.9	42
553	Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 638295.	2.8	6
554	The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data. Clinical Breast Cancer, 2022, 22, 10-25.	2.4	7
555	Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer. Clinical Cancer Research, 2021, 27, 5681-5687.	7.0	18
557	An update of new small-molecule anticancer drugs approved from 2015 to 2020. European Journal of Medicinal Chemistry, 2021, 220, 113473.	5.5	27
558	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i> , <i>BRCA2</i> , or <i>PALB2</i> . Journal of Clinical Oncology, 2021, 39, 2497-2505.	1.6	113
559	A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2021, 88, 887-897.	2.3	6
560	The evolving role of PARP inhibitors in advanced ovarian cancer. Forum of Clinical Oncology, 2021, 12, 82-104.	0.2	0
561	Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer. Environmental Science and Pollution Research, 2021, 28, 49491-49506.	5.3	0
562	Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precision Oncology, 2021, 5, 1285-1296.	3.0	8
564	Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecologic Oncology, 2021, 162, 482-495.	1.4	31
565	Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. Journal of Investigative Dermatology, 2021, 141, 2028-2036.e2.	0.7	17
566	Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. Gynecologic Oncology, 2021, 162, 728-734.	1.4	4

	CHAIION	REPORT	
#	Article	IF	CITATIONS
567	Molecular Pathology of Ovarian Epithelial Neoplasms. Surgical Pathology Clinics, 2021, 14, 415-428.	1.7	2
568	Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers. Gynecologic Oncology, 2021, 163, 220-228.	1.4	4
569	Ovarian Cancer–Specific <i>BRCA</i> -like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. Clinical Cancer Research, 2021, 27, 6559-6569.	7.0	9
570	Targeting ARID1A mutations in cancer. Cancer Treatment Reviews, 2021, 100, 102287.	7.7	63
571	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. Cancer Treatment Reviews, 2021, 99, 102255.	7.7	25
572	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Gynecologic Oncology, 2021, 163, 490-497.	1.4	20
573	Poly (ADP-ribose) polymerase-1 (PARP1) as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome Blood Advances, 2021, 5, 4794-4805.	5.2	13
574	Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. Lung Cancer, 2021, 161, 180-188.	2.0	14
575	Principles of radiation therapy and chemotherapy in gynecologic cancer. , 2022, , 618-636.e1.		2
576	Malignant diseases of the ovary, fallopian tube, and peritoneum. , 2022, , 707-753.e7.		2
577	Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. Diagnostics, 2021, 11, 199.	2.6	24
578	The role of PARP inhibitors in <i>BRCA</i> mutated pancreatic cancer. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110148.	3.2	21
579	The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. Clinical Medicine Insights: Oncology, 2021, 15, 117955492199628.	1.3	33
580	Role of Next-Generation Sequencing Technologies in Personalized Medicine. , 2020, , 125-154.		13
581	Genomic Cancer Risk Assessment. , 2020, , 187-207.		1
582	PARP inhibition in the ovarian cancer patient: Current approvals and future directions. , 2020, 213, 107588.		7
583	Molecular subtypes of pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 207-220.	17.8	573
584	Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. Bioscience Reports, 2020, 40, .	2.4	13

#	Article	IF	CITATIONS
591	Repositioning PARP inhibitors for SARSâ€CoVâ€2 infection(COVIDâ€19); a new multiâ€pronged therapy for acute respiratory distress syndrome?. British Journal of Pharmacology, 2020, 177, 3635-3645.	5.4	52
592	Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC highâ€risk Chinese individuals. Cancer Science, 2020, 111, 647-657.	3.9	22
593	Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. International Journal of Gynecological Cancer, 2020, 30, 89-93.	2.5	30
594	A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. Journal of Clinical Investigation, 2018, 128, 2116-2126.	8.2	100
595	XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097420.	3.2	10
596	Genomic Alteration in Metastatic Breast Cancer and Its Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 30-43.	3.8	107
597	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 358-369.	3.8	8
598	Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget, 2017, 8, 73240-73257.	1.8	40
599	Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget, 2017, 8, 43653-43661.	1.8	85
600	Loss of <i>BRCA1</i> promotor hypermethylation in recurrent high-grade ovarian cancer. Oncotarget, 2017, 8, 83063-83074.	1.8	20
601	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget, 2017, 8, 104430-104443.	1.8	5
602	Genomic loss of heterozygosity and survival in the REAL3 trial. Oncotarget, 2018, 9, 36654-36665.	1.8	13
603	Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. Oncotarget, 2019, 10, 2855-2868.	1.8	13
604	PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. , 2019, 2, 665-679.		20
605	Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology. , 2019, 2, 608-617.		3
606	Current practices on genetic testing in ovarian cancer. Annals of Translational Medicine, 2020, 8, 1703-1703.	1.7	7
607	Translational research and application of basic biology to clinical trial development in GI cancers. Annals of Translational Medicine, 2018, 6, 164-164.	1.7	6
608	Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?. Annals of Translational Medicine, 2020, 8, 1706-1706.	1.7	17

#	Article	IF	CITATIONS
609	Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 370-382.	2.2	18
610	Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Current Drug Targets, 2020, 21, 167-178.	2.1	10
611	Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 206-212.	1.7	6
612	Hereditary ovarian cancers: state of the art. Minerva Medica, 2019, 110, 301-319.	0.9	15
613	New medical approaches in advanced ovarian cancer. Minerva Medica, 2019, 110, 367-384.	0.9	6
614	PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. Cancers, 2020, 12, 394.	3.7	91
615	The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. Cancers, 2020, 12, 2805.	3.7	30
616	Wise Management of Ovarian Cancer: On the Cutting Edge. Journal of Personalized Medicine, 2020, 10, 41.	2.5	51
617	The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. Journal of Immunotherapy and Precision Oncology, 2020, 3, 157-164.	1.4	2
618	Integration of PARP-inhibitors in ovarian cancer therapy. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 171-182.	0.8	3
619	Pharmacological ascorbate induces â€~BRCAness' and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer. Oncology Letters, 2020, 19, 2629-2638.	1.8	8
620	PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review). Oncology Letters, 2020, 20, 1-1.	1.8	16
621	Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer. Obstetrics and Gynecology Science, 2020, 63, 643-654.	1.6	4
622	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	4.9	314
623	Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes. , 2021, , 135-166.		0
624	Cutting-Edge Technologies for Ovarian Cancer: An Overview of the Impact of Genetic Testing, Next-Generation Sequencing, and Single-Cell Analysis. , 2021, , 203-229.		0
625	The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers. , 2021, , 59-133.		0
626	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. Journal of Gynecologic Oncology, 2021, 32, e95.	2.2	5

#	Addicie	IF	CITATIONS
π	Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry		CHAHONS
627	based proteomics. Journal of Ovarian Research, 2021, 14, 140.	3.0	8
628	The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing. Journal of Experimental and Clinical Cancer Research, 2021, 40, 338.	8.6	12
629	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynecology and Obstetrics, 2021, 155, 61-85.	2.3	145
630	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic Oncology, 2021, 163, 246-253.	1.4	62
631	Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction. Frontiers in Oncology, 2021, 11, 675972.	2.8	21
632	A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes. Biomedicines, 2021, 9, 1384.	3.2	4
633	ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide. Oncotarget, 2021, 12, 2114-2130.	1.8	3
634	Preexisting <i>TP53</i> -Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. JAMA Oncology, 2021, 7, 1772.	7.1	44
635	Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers. Genes, 2021, 12, 1593.	2.4	2
636	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. Cancers, 2021, 13, 5299.	3.7	2
637	Poly(ADP-Ribose) Polymerase Inhibitors and Myeloid Neoplasm Risk—Clues to a Mechanistic Connection?. JAMA Oncology, 2021, 7, 1763.	7.1	0
639	Gynecological Symptoms. , 2018, , 505-526.		0
641	Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer. Cureus, 2018, 10, e2685.	0.5	2
642	Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations. Drugs in Context, 2018, 7, 1-9.	2.2	3
644	Time to go functional! Determining tumors' DNA repair capacity ex vivo. Oncotarget, 2018, 9, 36826-36827.	1.8	0
645	Advances in the Treatment of Endometrial and Ovarian Cancer. Oncology & Hematology Review, 2019, 15, 23.	0.2	0
646	Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors. European Oncology and Haematology, 2019, 15, 29.	0.0	1
647	Genetics and Epigenetics of Mesothelioma. , 2019, , 45-67.		0

	CITATION	Report	
#	ARTICLE	IF	CITATIONS
649	Molecular Testing in Ovarian Cancer: Recommendations and Treatment Considerations. , 2020, , 171-186.		0
650	Genetics and the Gynecologic Patient. Ochsner Journal, 2020, 20, 446-451.	1.1	3
652	Unravelling the Mysteries of the Human Brain (Vol. 24, No. 8, Full Issue). Asia Pacific Biotech News, 2020, 24, .	0.0	0
653	U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review. Clinical Cancer Research, 2022, 28, 1058-1071.	7.0	11
654	Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls. Gynecologic Oncology, 2021, 163, 217-219.	1.4	1
655	Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data. Advances in Therapy, 2022, 39, 328-345.	2.9	9
656	Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy. Current Cancer Drug Targets, 2020, 20, 853-867.	1.6	1
658	Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. Targeted Oncology, 2021, 16, 59-68.	3.6	9
660	Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine. Genes and Diseases, 2022, 9, 668-681.	3.4	12
661	Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer. , 2020, 1, 26-52.		0
662	Current and Future Directions for PARP Inhibition. Journal of the Advanced Practitioner in Oncology, 2020, 11, 297-300.	0.4	0
663	Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma. Frontiers in Oncology, 2021, 11, 666815.	2.8	9
664	Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score. Clinical Cancer Research, 2022, 28, 1412-1421.	7.0	46
665	Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review. P and T, 2018, 43, 549-556.	0.9	9
666	CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. American Journal of Cancer Research, 2020, 10, 1140-1155.	1.4	9
668	Treatment algorithm in patients with ovarian cancer. Facts, Views & Vision in ObGyn, 2020, 12, 227-239.	1.1	2
669	PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review. Advances in Genetics, 2021, 108, 35-80.	1.8	5
670	Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. Cancer Letters, 2022, 526, 41-52.	7.2	9

#	Article	IF	CITATIONS
672	Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations. Frontiers in Pharmacology, 2021, 12, 743073.	3.5	10
673	BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report. Genes, 2021, 12, 1917.	2.4	2
674	Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. British Journal of Cancer, 2022, 126, 576-585.	6.4	7
675	Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study. Clinical Cancer Research, 2022, 28, 653-661.	7.0	10
676	Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study. Annals of Translational Medicine, 2021, 9, 1661-1661.	1.7	11
677	Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. European Journal of Cancer, 2021, 159, 283-295.	2.8	24
678	Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer. Reproductive Biology and Endocrinology, 2021, 19, 178.	3.3	17
679	Comparison of somatic mutation landscapes in Chinese versus European breast cancer patients. Human Genetics and Genomics Advances, 2021, 3, 100076.	1.7	3
680	European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Annals of Oncology, 2022, 33, 276-287.	1.2	68
682	Chrysin impairs genomic stability by suppressing DNA double-strand break repair in breast cancer cells. Cell Cycle, 2022, 21, 379-391.	2.6	8
683	Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer. Neoplasia, 2022, 24, 63-75.	5.3	14
684	Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 432-440.	2.0	5
685	The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance. Cancer Journal (Sudbury, Mass), 2021, 27, 491-500.	2.0	4
686	Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <i>BRCA1/2</i> -Mutated Breast Cancer. Clinical Cancer Research, 2022, 28, 1383-1390.	7.0	12
687	Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. BMC Cancer, 2022, 22, 13.	2.6	15
688	Examining the prevalence of homologous recombination repair defects in ER+ breast cancers. Breast Cancer Research and Treatment, 2022, 192, 649.	2.5	2
689	Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. European Journal of Hospital Pharmacy, 2023, 30, 328-332.	1.1	4
690	<i>NTRK</i> gene fusions are detected in both secretory and nonâ€secretory breast cancers. Pathology International, 2022, 72, 187-192.	1.3	9

#	Article	IF	CITATIONS
691	Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups. Gynecologic Oncology, 2022, 164, 558-565.	1.4	9
692	<scp>PARP</scp> mediated <scp>DNA</scp> damage response, genomic stability and immune responses. International Journal of Cancer, 2022, 150, 1745-1759.	5.1	18
693	The key players of parthanatos: opportunities for targeting multiple levels in the therapy of parthanatos-based pathogenesis. Cellular and Molecular Life Sciences, 2022, 79, 60.	5.4	35
694	Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy. Npj Precision Oncology, 2022, 6, 7.	5.4	11
695	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecologic Oncology, 2022, 164, 245-253.	1.4	15
696	Therapeutic Targeting of DNA Damage Response in Cancer. International Journal of Molecular Sciences, 2022, 23, 1701.	4.1	26
697	Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment. European Journal of Cancer, 2022, 163, 44-54.	2.8	14
698	Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers. Gynecologic Oncology, 2022, 165, 49-52.	1.4	15
699	Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine. Frontiers in Bioengineering and Biotechnology, 2022, 10, 836984.	4.1	22
700	Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review. Future Oncology, 2022, 18, 1627-1650.	2.4	3
701	The role of PARP inhibitors in gastrointestinal cancers. Critical Reviews in Oncology/Hematology, 2022, 171, 103621.	4.4	7
702	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. Critical Reviews in Oncology/Hematology, 2021, 168, 103539.	4.4	11
703	The Use of Targeted Agents in the Treatment of Gynecologic Cancers. Current Treatment Options in Oncology, 2022, 23, 15-28.	3.0	3
704	Neurological complications of gynecological cancers. , 2022, , 353-364.		0
705	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations. Cancers, 2022, 14, 1132.	3.7	8
706	PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. OncoTargets and Therapy, 2022, Volume 15, 165-180.	2.0	15
707	RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?. Expert Review of Molecular Diagnostics, 2022, 22, 185-199.	3.1	16
708	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. Cancers, 2022, 14, 1253.	3.7	69

		CITATION RE	PORT	
#	Article		IF	CITATIONS
709	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. Cancers, 2022, 14,	1003.	3.7	18
710	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targetin Cancers, 2022, 14, 953.	g Agents.	3.7	16
711	Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. The Library, 2022, 2022, CD007929.	2 Cochrane	2.8	22
712	Guidelines for Management of Treatment-Emergent Adverse Events During Rucapario Patients with Metastatic Castration-Resistant Prostate Cancer. Cancer Management a 2022, Volume 14, 673-686.	Treatment of nd Research,	1.9	4
713	Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cance Olaparib Monotherapy. Current Cancer Drug Targets, 2022, 22, 530-536.	r Treated with	1.6	4
714	Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategi Therapeutic Responses to PARP Inhibition. Cancers, 2022, 14, 897.	es to Improve	3.7	13
715	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovaria Medical Perspectives. Cancers, 2022, 14, 1098.	n Cancer Part 2:	3.7	8
716	Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelia Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italia Anticancer Research, 2022, 42, 2017-2022.	l Ovarian In Study.	1.1	8
717	Integrating Precision Medicine into the Contemporary Management of Gynecologic Ca Oncology Reports, 2022, 24, 889-904.	ancers. Current	4.0	3
718	Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic BRCA1/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Gener Cancers, 2022, 14, 1434.	Variants in ation Sequencing.	3.7	6
719	Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colo Cancers, 2022, 14, 1388.	prectal Cancer.	3.7	22
720	Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Oppc Targeted Therapy. Diagnostics, 2022, 12, 842.	rtunity for	2.6	15
721	Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma. C Communication and Signaling, 2022, 20, 39.	ell	6.5	0
722	Practice guidelines for <i>BRCA1/2</i> tumour testing in ovarian cancer. Journal of Me 2022, 59, 727-736.	dical Genetics,	3.2	4
723	Templated Insertions Are Associated Specifically with <i>BRCA2</i> Deficiency and Ov Advanced Ovarian Cancer. Molecular Cancer Research, 2022, 20, 1061-1070.	erall Survival in	3.4	1
724	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Prov Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.	visional Clinical	1.6	96
725	A phase I study of talazoparib (<scp>BMN</scp> 673) combined with carboplatin and patients with advanced solid tumors (<scp>NCI9782</scp>). Cancer Medicine, 2022,	paclitaxel in 11, 3969-3981.	2.8	11
726	Rucaparib for BRCA1/2-mutated pretreated ovarian cancer: reflections from the ARIEL Oncology, The, 2022, 23, 440-441.	trial. Lancet	10.7	1

#	Article	IF	CITATIONS
727	Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 465-478.	10.7	70
728	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. European Journal of Cancer, 2022, 166, 87-99.	2.8	21
729	Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. JCI Insight, 2021, 6, .	5.0	15
730	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers, 2021, 13, 6385.	3.7	19
731	The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers. Journal of Hematology and Oncology, 2021, 14, 206.	17.0	24
732	Targeting DNA repair pathway in cancer: Mechanisms and clinical application. MedComm, 2021, 2, 654-691.	7.2	34
733	Organoids and epithelial ovarian cancer †a future tool for personalized treatment decisions?. Molecular and Clinical Oncology, 2021, 16, 29.	1.0	2
734	Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer. Pharmaceuticals, 2021, 14, 1270.	3.8	5
735	Identification of molecular subtypes and prognostic signature for hepatocellular carcinoma based on genes associated with homologous recombination deficiency. Scientific Reports, 2021, 11, 24022.	3.3	5
736	Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma. Frontiers in Oncology, 2021, 11, 603591.	2.8	3
737	Artificial intelligence, molecular subtyping, biomarkers, and precision oncology. Emerging Topics in Life Sciences, 2021, 5, 747-756.	2.6	1
738	Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Research, 2022, 82, 1646-1657.	0.9	40
739	Appropriate Selection of PARP Inhibitors in Ovarian Cancer. Current Treatment Options in Oncology, 2022, 23, 887-903.	3.0	17
740	PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opinion on Investigational Drugs, 2022, 31, 607-631.	4.1	20
741	Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors. Cancer Chemotherapy and Pharmacology, 2022, 89, 671-682.	2.3	7
742	An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 683-695.	2.3	6
745	Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas. Npj Precision Oncology, 2022, 6, 29.	5.4	6
746	Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies. Expert Review of Proteomics, 2022, 19, 115-129.	3.0	3

#	Article	IF	CITATIONS
747	Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer. Journal of Central South University (Medical Sciences), 2021, 46, 644-652.	0.1	0
748	Altered Signaling Pathways Revealed by Comprehensive Genomic Profiling in Patients With Unknown Primary Tumors. Frontiers in Oncology, 2022, 12, 753311.	2.8	1
752	Development of 1-(4-(Substituted)piperazin-1-yl)-2-((2-((4-methoxybenzyl)thio)pyrimidin-4-yl)oxy)ethanones That Target Poly (ADP-Ribose) Polymerase in Human Breast Cancer Cells. Molecules, 2022, 27, 2848.	3.8	5
753	Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors. Molecular Cancer Therapeutics, 2022, 21, 1115-1124.	4.1	3
754	The Landscape of Personalized Medicine in Gynecologic Cancer. Advances in Oncology, 2022, 2, 99-105.	0.2	1
755	Investigation of BRCA1 methylation and FAT3 mutation as a potential biomarker in ovarian cancer samples. , 2022, 33, 201032.		1
757	The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients. Critical Reviews in Oncology/Hematology, 2022, 175, 103725.	4.4	1
758	Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance. Cancers, 2022, 14, 2504.	3.7	12
759	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications, 2022, 13, .	12.8	68
760	Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?. Cancers, 2022, 14, 2561.	3.7	4
761	Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells. Medical Sciences (Basel, Switzerland), 2022, 10, 28.	2.9	4
762	Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecologic Oncology, 2022, 166, 351-357.	1.4	8
763	Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions. Surgical Pathology Clinics, 2022, , .	1.7	0
764	Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review. Kreativnaâ Hirurgiâ I Onkologiâ, 2022, 12, 48-55.	0.3	0
766	A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 662-6.	2.1	1
767	Ovarian cancer recurrence: "is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?â€: Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 451-458.	2.1	6
768	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45). Journal of Clinical Oncology, 2022, 40, 3952-3964.	1.6	125
769	A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. Current	2.2	1

#	Article	IF	CITATIONS
770	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 2022, 13, .	12.8	51
771	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. Cancers, 2022, 14, 2950.	3.7	9
772	Breast cancer in the era of precision medicine. Molecular Biology Reports, 2022, 49, 10023-10037.	2.3	19
774	Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. European Journal of Cancer, 2022, 171, 232-241.	2.8	7
775	Molecular Mechanisms of Parthanatos and Its Role in Diverse Diseases. International Journal of Molecular Sciences, 2022, 23, 7292.	4.1	31
776	Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion. Facts, Views & Vision in ObGyn, 2022, 14, 111-120.	1.1	1
777	Clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on CD133 and HE4 expression in advanced epithelial ovarian cancer. Pakistan Journal of Medical Sciences, 2022, 38, .	0.6	0
778	Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?. South Asian Journal of Cancer, 0, , .	0.6	0
779	Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis. Gynecologic Oncology, 2022, 166, 425-431.	1.4	12
780	Reconsidering the mechanisms of action of <scp>PARP</scp> inhibitors based on clinical outcomes. Cancer Science, 2022, 113, 2943-2951.	3.9	11
781	Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer. International Journal of Environmental Research and Public Health, 2022, 19, 8577.	2.6	49
782	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. JCO Precision Oncology, 2022, , .	3.0	10
783	Niraparib treatment for patients with <i>BRCA</i> -mutated ovarian cancer: review of clinical data and therapeutic context. Future Oncology, 2022, 18, 2505-2536.	2.4	4
784	Identification of Ubiquitin-Related Gene-Pair Signatures for Predicting Tumor Microenvironment Infiltration and Drug Sensitivity of Lung Adenocarcinoma. Cancers, 2022, 14, 3478.	3.7	1
785	The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 8125.	4.1	9
786	Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance. International Journal of Gynecological Cancer, 2022, 32, 1164-1170.	2.5	12
787	Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy. Molecules, 2022, 27, 4736.	3.8	10
788	Hematological toxicities in <scp>PARP</scp> inhibitors: A realâ€world study using <scp>FDA</scp> adverse event reporting system (<scp>FAERS</scp>) database. Cancer Medicine, 2023, 12, 3365-3375.	2.8	18

#	Article	IF	CITATIONS
789	Epithelial tumor compartment- and adjacent stromal compartment-specific expression of PARP1 in different anatomical sites in patients with HGSOC. Genome Instability & Disease, 2022, 3, 201-208.	1.1	0
791	A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. Journal of Clinical Oncology, 2023, 41, 54-64.	1.6	17
792	Life after SOLO-2: Is Olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi) resistant, recurrent ovarian cancer?. Annals of Oncology, 2022, , .	1.2	5
793	PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies. Frontiers in Pharmacology, 0, 13, .	3.5	10
794	Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma. Genes, 2022, 13, 1398.	2.4	1
795	BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. Cancers, 2022, 14, 3888.	3.7	56
796	Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial. Clinical Cancer Research, 2022, 28, 4186-4193.	7.0	20
798	Bioinformatics: From NCS Data to Biological Complexity in Variant Detection and Oncological Clinical Practice. Biomedicines, 2022, 10, 2074.	3.2	10
799	CDCA3 exhibits a role in promoting the progression of ovarian cancer. Tissue and Cell, 2022, 79, 101903.	2.2	3
800	Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients. Pathology Research and Practice, 2022, 238, 154074.	2.3	4
801	The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine. International Journal of Molecular Sciences, 2022, 23, 9981.	4.1	2
802	Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology. Cancers, 2022, 14, 4157.	3.7	5
803	Identification of Shared Neoantigens in BRCA1-Related Breast Cancer. Vaccines, 2022, 10, 1597.	4.4	3
804	Impact of BRCA Gene Testing on Ovarian Cancer Management. European Journal of Medical and Health Sciences, 2022, 4, 1-6.	0.2	0
805	A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i> -associated ovarian cancer. Siberian Journal of Oncology, 2022, 21, 156-164.	0.3	0
806	Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib. Clinical Pharmacokinetics, 2022, 61, 1477-1493.	3.5	6
807	HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data. Frontiers in Genetics, 0, 13, .	2.3	1
808	Leveraging an Informatics Approach to Identify an Unmet Clinical Need for <i>BRCA1</i> / <i>2</i> Testing Among Patients With Ovarian Cancer. JCO Clinical Cancer Informatics, 2022, , .	2.1	0

#	Article	IF	Citations
809	PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer. , 0, , .		0
810	Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. Clinical Cancer Research, 2023, 29, 40-49.	7.0	3
811	Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombinationâ€deficient hepatocellular carcinoma. Hepatology, 2023, 78, 452-467.	7.3	3
813	Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers. Cancers, 2022, 14, 4724.	3.7	0
815	Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. Cancers, 2022, 14, 4621.	3.7	3
816	Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors. OncoTargets and Therapy, 0, Volume 15, 1105-1117.	2.0	7
817	Treatment of Advanced-Stage Ovarian Cancer. , 2022, , 105-119.		0
818	Personalized Treatment in Ovarian Cancer. Comprehensive Gynecology and Obstetrics, 2022, , 1-19.	0.0	0
819	Integrated Molecular Analysis Reveals 2 Distinct Subtypes of Pure Seminoma of the Testis. Cancer Informatics, 2022, 21, 117693512211326.	1.9	8
820	Clinical Relevance of BRCA1/2 Pathogenic Variants and Impaired DNA Repair Pathways in Ovarian Carcinomas. Comprehensive Gynecology and Obstetrics, 2022, , 59-76.	0.0	0
822	State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. JCO Precision Oncology, 2022, , .	3.0	2
824	Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. Clinical Pharmacokinetics, 2022, 61, 1649-1675.	3.5	23
825	Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. Biomedicines, 2022, 10, 2511.	3.2	10
826	Small molecule inhibitors targeting the cancers. MedComm, 2022, 3, .	7.2	25
827	Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report. Cureus, 2022, , .	0.5	0
828	DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer. Gynecologic Oncology, 2022, , .	1.4	1
829	Integrative Genomic Tests in Clinical Oncology. International Journal of Molecular Sciences, 2022, 23, 13129.	4.1	8
830	Exploring the DNA damage response pathway for synthetic lethality. Genome Instability & Disease, 2023, 4, 98-120.	1.1	2

#	Article	IF	CITATIONS
832	Molecular hallmarks of cancer. , 2023, , 489-505.e5.		0
833	Epithelial ovarian cancer. , 2023, , 250-281.e8.		0
834	Targeted therapy and molecular genetics. , 2023, , 464-488.e11.		0
835	Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse. Current Oncology Reports, 2022, 24, 1685-1693.	4.0	6
836	BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy. Cancers, 2022, 14, 5619.	3.7	3
837	Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma. Cells, 2022, 11, 3563.	4.1	1
838	<scp>Pyrroleâ€based EGFR</scp> inhibitors for the treatment of <scp>NCSLC</scp> : Binding modes and <scp>SARs</scp> investigations. Chemical Biology and Drug Design, 2023, 101, 195-217.	3.2	2
839	Avelumab Plus Talazoparib in Patients With <i>BRCA1/2</i> - or <i>ATM</i> -Altered Advanced Solid Tumors. JAMA Oncology, 2023, 9, 29.	7.1	21
840	Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. Breast Cancer Research, 2022, 24, .	5.0	4
841	PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer. European Medical Journal Oncology, 0, , 68-76.	0.0	1
842	The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture. European Medical Journal Oncology, 0, , 2-15.	0.0	0
843	Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?. International Journal of Gynecological Cancer, 2023, 33, 607-618.	2.5	1
844	[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study. Clinical Cancer Research, 2023, 29, 1515-1527.	7.0	6
845	DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. International Journal of Molecular Sciences, 2022, 23, 14672.	4.1	26
846	Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. Biomedicines, 2022, 10, 3008.	3.2	0
847	Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test. BMC Cancer, 2022, 22, .	2.6	4
848	Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations. BMC Cancer, 2022, 22, .	2.6	2
849	The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nature Genetics. 2022. 54. 1853-1864.	21.4	24

#	ARTICLE	IF	CITATIONS
850	Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report. Frontiers in Oncology, 0, 12, .	2.8	1
851	Towards Personalized Management of Ovarian Cancer. Cancer Management and Research, 0, Volume 14, 3469-3483.	1.9	4
852	Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. Journal of Immunotherapy and Precision Oncology, 2023, 6, 31-49.	1.4	1
853	Targeting DNA damage response pathways in cancer. Nature Reviews Cancer, 2023, 23, 78-94.	28.4	158
854	Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. British Journal of Cancer, 0, , .	6.4	2
855	Shallow Whole-Genome Sequencing of Cell-Free DNA (cfDNA) Detects Epithelial Ovarian Cancer and Predicts Patient Prognosis. Cancers, 2023, 15, 530.	3.7	0
856	Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. Journal of Ovarian Research, 2023, 16, .	3.0	8
857	DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities. Cancers, 2023, 15, 448.	3.7	7
858	Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. Annals of Pharmacotherapy, 0, , 106002802211491.	1.9	0
860	Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?. South Asian Journal of Cancer, 2022, 11, 207-212.	0.6	0
861	Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer. Npj Precision Oncology, 2022, 6, .	5.4	8
862	Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601. Anti-Cancer Drugs, 2023, 34, 857-865.	1.4	2
863	Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2023, Publish Ahead of Print, .	2.0	1
864	Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. JCO Precision Oncology, 2023, , .	3.0	13
865	Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy. International Journal of Clinical Oncology, 0, , .	2.2	0
866	The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology, 2023, 170, 172-178.	1.4	0
867	Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention. Biomolecules, 2023, 13, 653.	4.0	0
868	The Role of PARP Inhibitors in the Treatment of Advanced Epithelial Ovarian Carcinoma. , 2022, ,		0

#	Article	IF	CITATIONS
869	Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. Biology, 2023, 12, 218.	2.8	27
870	Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis. Expert Review of Anticancer Therapy, 2023, 23, 207-216.	2.4	2
871	Pyrosequencing Assay for BRCA1 Methylation Analysis. Journal of Molecular Diagnostics, 2023, 25, 217-226.	2.8	1
872	The PARP inhibitor Rucaparib synergizes with radiation to attenuate atypical teratoid rhabdoid tumor growth. Neuro-Oncology Advances, 2023, 5, .	0.7	1
873	Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. Genomics, Proteomics and Bioinformatics, 2023, , .	6.9	2
874	Small-Molecule–Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death. Molecular Cancer Therapeutics, 2023, 22, 599-615.	4.1	9
875	Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & amp; STUDY 10. EBioMedicine, 2023, 89, 104477.	6.1	2
876	Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular Cancer Therapeutics, 2023, 22, 333-342.	4.1	2
877	New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. International Journal of Molecular Sciences, 2023, 24, 4044.	4.1	0
878	Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. Cancers, 2023, 15, 1299.	3.7	5
879	Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies. Molecular Therapy - Oncolytics, 2023, 28, 293-306.	4.4	2
880	Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311576.	3.2	3
881	Analysis of BRCA1 and BRCA2 alternative splicing in predisposition to ovarian cancer. Experimental and Molecular Pathology, 2023, 130, 104856.	2.1	0
882	Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. Oncologist, 2023, 28, 319-326.	3.7	1
883	Personalized Systemic Therapies in Hereditary Cancer Syndromes. Genes, 2023, 14, 684.	2.4	4
884	Genomic testing in high-grade serous ovarian cancer: current options and future development. International Journal of Gynecological Cancer, 2023, 33, 358-363.	2.5	0
885	Overcoming PARP inhibitor resistance in ovarian cancer. International Journal of Gynecological Cancer, 2023, 33, 364-376.	2.5	4
886	Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer. Medicine (United States), 2023, 102, e33271.	1.0	0

#	Article	IF	CITATIONS
887	Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel. Journal of Molecular Diagnostics, 2023, 25, 295-310.	2.8	1
888	Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer. Frontiers in Pharmacology, 0, 14, .	3.5	4
889	Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. Journal of Ovarian Research, 2023, 16, .	3.0	2
890	Clinical Targeted Next-Generation Panel Sequencing Reveals <i>MYC</i> Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precision Oncology, 2023, , .	3.0	2
892	Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit. ESMO Open, 2023, 8, 101209.	4.5	1
893	PARP Inhibitors in Breast and Ovarian Cancer. Cancers, 2023, 15, 2357.	3.7	9
894	Targeted therapy. , 2023, , 205-411.		0
895	RAD50 Deficient in a Breast Cancer Model Predicts Sensitivity to PARP Inhibitors. Current Cancer Drug Targets, 2023, 23, .	1.6	0
896	Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon. Gynecologic Oncology Reports, 2023, 47, 101186.	0.6	1
897	Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor. Biomedicine and Pharmacotherapy, 2023, 163, 114770.	5.6	0
898	RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer. Clinical Cancer Research, 2023, 29, 2466-2479.	7.0	7
900	Targeting DNA damage repair precision medicine strategies in cancer. Current Opinion in Pharmacology, 2023, 70, 102381.	3.5	2
901	High-grade serous ovarian carcinoma organoids as models of chromosomal instability. ELife, 0, 12, .	6.0	7
902	Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays. JCO Precision Oncology, 2023, , .	3.0	2
904	PARP Inhibitors in Ovarian Cancer: A Review. Targeted Oncology, 2023, 18, 471-503.	3.6	7
905	Prevalence of germline mutations in women with breast and/or ovarian cancer in a tertiary care center in Pune, India. International Journal of Molecular and Immuno Oncology, 0, 8, 65-71.	0.0	1
906	The power of whole genomic sequencing in biomedical research and clinical applications. , 2024, , 1-18.		0
907	Recent advances in targeted therapy for ovarian cancer. , 2022, 8, 28-35.		0

#		IF	CITATIONS
π 908	New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions. Cancer and Metastasis Reviews, 2023, 42, 891-925.	5.9	5
909	Management of Advanced Prostate Cancer in the Precision Oncology Era. Cancers, 2023, 15, 2552.	3.7	3
910	Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188910.	7.4	3
911	LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring. Pharmaceutics, 2023, 15, 1524.	4.5	2
912	The landscape of <scp><i>BRCA1</i></scp> and <scp><i>BRCA2</i></scp> large rearrangements in an international cohort of over 20 000 ovarian tumors identified using nextâ€generation sequencing. Genes Chromosomes and Cancer, 2023, 62, 589-596.	2.8	1
913	Impact of DNA damage repair alterations on prostate cancer progression and metastasis. Frontiers in Oncology, 0, 13, .	2.8	3
914	Targeted therapies in ovarian cancer: where we stand and where we are heading. Journal of the Korean Medical Association, 2023, 66, 384-392.	0.3	0
915	Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer. Cancer Research Communications, 2023, 3, 1514-1523.	1.7	0
917	The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities. Cancer Drug Resistance (Alhambra, Calif), 0, , 499-516.	2.1	0
918	The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma. Nature Communications, 2023, 14, .	12.8	5
919	A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data. BMC Cancer, 2023, 23, .	2.6	2
920	Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer. International Journal of Clinical Oncology, 2023, 28, 1554-1562.	2.2	1
921	Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation. International Journal of Molecular Sciences, 2023, 24, 13219.	4.1	3
922	Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours. International Journal of Molecular Sciences, 2023, 24, 13454.	4.1	1
923	Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. Npj Breast Cancer, 2023, 9, .	5.2	1
924	Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?. Critical Reviews in Oncology/Hematology, 2023, 190, 104086.	4.4	2
925	Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clinical Cancer Research, 2023, 29, 3691-3705.	7.0	1
926	ShallowHRD status acts as an effective prognostic predictor in ovarian cancer patients treated by poly (ADP-ribose) polymerase inhibitors (PARPis). Journal of Cancer Research and Clinical Oncology, 2023, 149, 15839-15844.	2.5	0

#	Article	IF	CITATIONS
927	SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer. International Journal of Molecular Sciences, 2023, 24, 14212.	4.1	0
928	Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response. JCO Precision Oncology, 2023, , .	3.0	2
929	Recurrent Ovarian Cancer. , 2023, , 53-63.		0
930	Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages. Cell Reports, 2023, 42, 113256.	6.4	0
931	Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in <i>BRCA</i> -mutated cancer. Science Advances, 2023, 9, .	10.3	2
932	Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-NaÃ ⁻ ve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 2024, 30, 50-62.	7.0	2
933	Developments in Genetics: Better Management of Ovarian Cancer Patients. International Journal of Molecular Sciences, 2023, 24, 15987.	4.1	0
934	Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?. Cancer Treatment Reviews, 2023, 121, 102650.	7.7	2
935	Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer. Cancer Treatment and Research, 2023, , 71-89.	0.5	0
936	Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse. Journal of Ovarian Research, 2023, 16, .	3.0	0
937	Development of Homologous Recombination Functional Assays for Targeting the DDR. Cancer Treatment and Research, 2023, , 43-70.	0.5	0
938	The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models. Therapeutic Advances in Medical Oncology, 2023, 15, .	3.2	0
939	Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival. Gynecologic Oncology, 2024, 180, 35-43.	1.4	0
941	Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma. Annals of Oncology, 2023, 34, 1074-1076.	1.2	0
942	Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues. Pathology, 2024, 56, 214-227.	0.6	1
943	Ô¹Õ«Ö€Õ¡ÕÕjÕµÕ«Õ¶ Õ©Õ¥Ö€Õ¡ÕºÕ«Õ¡ÕµÕ« Ö‡ Õ«Õ´Õ,Ö,Õ¶Õ¡Õ©Õ¥Ö€Õ¡ÕºÕ«Õ¡ÕµÕ« Õ®҇¥Ö€Õ¨ Õ¹,	⁄4 @¥©Õ «(Õ Õ &Õ¾Õ _s Õ
944	ROS, Redox Regulation, and Anticancer Therapy. , 2023, , 311-409.		0
945	Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers. Cancer Cell, 2023, 41, 1963-1971.e3.	16.8	3

	Сітатіо	CITATION REPORT	
#	Article	IF	CITATIONS
947	Mutual Feedback Between Gynecological HBOC Practice and Cancer Genomic Medicine. , 2023, , 47-56.		0
948	Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study. Breast Cancer Research, 2023, 25, .	5.0	0
949	Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer. Critical Reviews in Oncology/Hematology, 2024, 194, 104238.	4.4	0
950	ADP-ribosylation: An emerging direction for disease treatment. Ageing Research Reviews, 2024, 94, 102176.	10.9	0
951	Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer. journal of applied laboratory medicine, The, 2024, 9, 76-91.	1.3	0
952	Antibody-Drug Conjugates in Gynecologic Cancers. Current Treatment Options in Oncology, 2024, 25, 1-19.	3.0	0
953	Next-generation sequencing-based analysis of homologous recombination repair gene variant in ovarian cancer. Heliyon, 2024, 10, e23684.	3.2	0
954	Suppression of NBS1 Upregulates CyclinB to Induce Olaparib Sensitivity in Ovarian Cancer. Technology in Cancer Research and Treatment, 2024, 23, .	1.9	0
955	Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro. International Journal of Molecular Sciences, 2024, 25, 886.	4.1	1
956	PARP inhibitors in ovarian cancer. Seminars in Oncology, 2024, 51, 45-57.	2.2	0
957	PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer. Journal of Gynecologic Oncology, 0, 35, .	2.2	0
958	PARP Inhibitors in Breast Cancer: a Short Communication. Current Oncology Reports, 2024, 26, 103-113.	4.0	0
959	Homologous repair deficiency and PARP inhibitors in cancer management. , 2024, , 257-274.		0
960	Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer. British Journal of Cancer, 2024, 130, 941-950.	6.4	0
961	Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer. Gynecologic Oncology, 2024, 184, 67-73.	1.4	0
962	The role of aberrant DNA methylation in cancer initiation and clinical impacts. Therapeutic Advances in Medical Oncology, 2024, 16, .	3.2	0
963	Evaluation of Homologous Recombination Deficiency in Ovarian Cancer. Current Treatment Options in Oncology, 2024, 25, 237-260.	3.0	0
964	<i>BRCA1</i> , <i>BRCA2</i> , and <i>TP53</i> germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer. Cancer Medicine, 2024, 13, .	2.8	0

ARTICLE IF CITATIONS # Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 965 1.4 0 15-year population-based analysis. Gynecologic Oncology, 2024, 184, 190-197. Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling 12.8 pathway. Nature Communications, 2024, 15, . Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition 967 5.4 0 and platinum chemotherapy. Npj Precision Oncology, 2024, 8, Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically 968 actionable genomic alterations and biomarkers. Frontiers in Oncology, 0, 14, . How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian 969 2.8 0 cancer: a review of literature. Frontiers in Oncology, Ó, 14, . $\mathsf{BRCA1/2}$ alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges. Frontiers in Oncology, 0, 14, . 2.8 Metastatic squamous cell carcinoma arising from mature teratoma of the ovary: Description of multi-modality treatment including incorporation of adjuvant immunotherapy and maintenance PARP inhibitor therapy. Gynecologic Oncology Reports, 2024, 52, 101371. 971 0.6 0 Identification of different subtypes of ovarian cancer and construction of prognostic models based 3.2 on glutamine-metabolism associated genes. Heliyon, 2024, 10, e27358. Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors 973 Lacking Evidence of Benefit: Focus in Ovarian Cancer. International Journal of Molecular Sciences, 4.1 0 2024, 25, 3173. Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug 974 2.5 assessment. Journal of Cancer Research and Clinical Oncology, 2024, 150, . Characteristics of germline DNA damage response gene mutations in ovarian cancer in Southwest 975 3.3 0 China. Scientific Reports, 2024, 14, .